- Home
- PCSA vs YCBD Comparison
PCSA vs YCBD Comparison
Compare PCSA & YCBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- YCBD
- Stock Information
- Founded
- PCSA 2011
- YCBD 2015
- Country
- PCSA United States
- YCBD United States
- Employees
- PCSA 13
- YCBD N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- YCBD Biotechnology: Pharmaceutical Preparations
- Sector
- PCSA Health Care
- YCBD Health Care
- Exchange
- PCSA Nasdaq
- YCBD Nasdaq
- Market Cap
- PCSA 1.2M
- YCBD 1.4M
- IPO Year
- PCSA N/A
- YCBD N/A
- Fundamental
- Price
- PCSA $0.24
- YCBD $0.26
- Analyst Decision
- PCSA Strong Buy
- YCBD
- Analyst Count
- PCSA 1
- YCBD 0
- Target Price
- PCSA $6.00
- YCBD N/A
- AVG Volume (30 Days)
- PCSA 6.0M
- YCBD 1.2M
- Earning Date
- PCSA 05-09-2025
- YCBD 05-14-2025
- Dividend Yield
- PCSA N/A
- YCBD N/A
- EPS Growth
- PCSA N/A
- YCBD N/A
- EPS
- PCSA N/A
- YCBD N/A
- Revenue
- PCSA N/A
- YCBD $19,220,238.00
- Revenue This Year
- PCSA N/A
- YCBD $13.00
- Revenue Next Year
- PCSA N/A
- YCBD $10.00
- P/E Ratio
- PCSA N/A
- YCBD N/A
- Revenue Growth
- PCSA N/A
- YCBD N/A
- 52 Week Low
- PCSA $0.22
- YCBD $0.18
- 52 Week High
- PCSA $3.10
- YCBD $1.25
- Technical
- Relative Strength Index (RSI)
- PCSA 32.49
- YCBD 48.26
- Support Level
- PCSA $0.20
- YCBD $0.21
- Resistance Level
- PCSA $0.25
- YCBD $0.25
- Average True Range (ATR)
- PCSA 0.06
- YCBD 0.03
- MACD
- PCSA 0.01
- YCBD 0.01
- Stochastic Oscillator
- PCSA 32.69
- YCBD 78.18
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.